Navigation Links
Antibodies in Medical Technology

Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients

... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody ...

Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients

... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... Its product development pipeline includes novel antibodies generated with its proprietary BiTE(R) antibody ...

Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies

... on two fully human anti-PS (phosphatidylserine) antibodies were presented by its collaboration partner ... that the anti-tumor effects observed with anti-PS antibodies reflect their immunomodulatory mechanism of ... in a preclinical model of prostate cancer. Both antibodies were isolated using Affitech's unique MBAS ...

Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day

... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... data presented at AACR demonstrated that BiTE antibodies developed from the EGFR-specific monoclonal antibodies Erbitux(R) (cetuximab) and Vectibix(R) ...

Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model

... Anti-Tumor Potential of Fully Human Anti-PS antibodies and Expand the Company's PS-Targeting Platform- ... biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus ... its fully human phosphatidylserine (PS)-targeting antibodies demonstrated encouraging signs of efficacy in a ...

Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells

... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... data indicate that after Micromet developed BiTE antibodies from the EGFR-specific monoclonal antibodies Erbitux(R) (cetuximab) and Vectibix(R) ...

Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer

... and safety data from multiple programs, including antibodies to novel and potentially important cancer targets ... Development of anti-Glypican 3 therapeutic antibodies (Abstract #1233) Glypican-3 is a protein that ... cancer. A panel of fully human anti-glypican-3 antibodies was generated from which a lead candidate, ...

Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies

... Studies Highlight the Ability of PS-Targeting antibodies to Reverse the Immune Suppressing Effects of ... - Studies Confirm Peregrine's PS-Targeting antibodies Stimulate Dendritic Cell Maturation, Inflammatory ... biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus ...

AACR Data Highlights InNexus Preclinical Antibody Candidate

... commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking ... commercializing the next generation of monoclonal antibodies based on its DXL technology, which improves the ... opening new markets and disease applications. DXL antibodies utilize unique, novel and patented methods and ...

Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203

... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... is focused on developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... antibody platform, representing a new class of antibodies that specifically activate T cells from the ...

Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients

... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... is focused on developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... antibody platform, representing a new class of antibodies that specifically activate T cells from the ...

YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY

... the monovalent binding to normal cells of other antibodies confirming that only nimotuzumab will avoid ... result of properties intrinsic to the individual antibodies or to the class. The results show that Erbitux(R) ... that results in its benign safety profile. Both antibodies bind definitively when binding bivalently. The ...

Micromet Key Events for 2009

... to 16, 2009: Update on several preclinical BiTE antibodies at the American Association for Cancer Research ... and 10, 2009, in New York, NY. About BiTE antibodies BiTE(R) antibodies are designed to direct the body's cytotoxic, ...

Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)

... tract infection. No patient tested positive for antibodies to ofatumumab.(1) "There is a great ... from the binding sites targeted by other CD20 antibodies currently available or in development.(5) The ... The Biological Activity of Human CD20 Monoclonal antibodies Is Linked to Unique Epitopes on CD20. J Immunol ...

Micromet Expands Committed Equity Financing Facility to $75 Million

... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... The Company is developing novel, proprietary antibodies for the treatment of cancer, inflammation and ... antibody platform to create a new class of antibodies that specifically activate T cells from the ...

Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells

... status. Recent studies suggest that anti-EGFR antibodies cetuximab (Erbitux(R); ImClone, BMS, Merck KGaA) ... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Four of its antibodies are currently in clinical trials, while the ...

Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation

... The research links naturally occurring antibodies against phosphorylcholine (PC) to ... and the prospects for development of therapeutic antibodies to treat cardiovascular inflammation. ... with Athera and the prospects for development of antibodies to phosphorylcholine include the risks that: ...

InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies

... commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking ... "The DXL(TM) technology platform builds better antibodies and soon you'll be able to see our strategy to ... mass" at the point of association. DXL(TM) antibodies have significantly extended dissociation rates, ...

Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy

... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Four of its antibodies are currently in clinical trials, while the ... of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new ...

Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies

... breast and colon cancer. PAN-622 and other antibodies covered under U.S. Patent Number 7,413,737 were ... KD. Isolation and characterization of human antibodies targeting human aspartyl ... notice of the issuance of the patent covering antibodies against HAAH, and particularly PAN-622, our ...

Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE

... developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Four of its antibodies are currently in clinical trials, while the ... BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, ...

Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab

... serum levels needed by conventional monoclonal antibodies for achieving a tumor regression in this disease. ... Officer Carsten Reinhardt, M.D. Typically antibodies cannot engage T cells because T cells lack ... to escape recognition by T cells. The use of antibodies that are specifically designed to engage T cells ...

MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research

... trial participants. MabVax plans to rescue antibodies from these patient samples to create a pipeline ... on the surface of the cancer cells. By rescuing antibodies from a selection of patients who generate a ... Vaccines, or passively administered antibodies developed from these vaccines, produced evidence ...

Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial

... by Genentech of the anti-CD4 monoclonal antibodies in autoimmune or other indications. Tolerx may ... on worldwide net sales of the anti-CD4 monoclonal antibodies that Genentech successfully develops. In lieu of ... and promote and enhance immune responses. These antibodies are being assessed for potential benefit in the ...

Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results

... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Four of its antibodies are currently in clinical trials, while the ... BiTE antibodies represent a new class of antibodies that activate the T cells of a patient's own ...

Abeome and Cato Research to Collaborate on Ovarian Cancer Therapeutic

... vastly improves the development of monoclonal antibodies and Abeome is deploying its technology to provide a shotgun approach to develop an array of antibodies for an ovarian cancer therapeutic target. The ... to develop such a large library of monoclonal antibodies by use of their technology. They have pushed ...

Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases

... company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Four of its antibodies are currently in clinical trials, while the ... BiTE antibodies represent a new class of antibodies that activate the T cells of a patient's own ...

Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia

... group (GMALL). About BiTE Antibodies BiTE(R) antibodies are designed to direct the body's cytotoxic, ... new therapeutic approach to cancer therapy. BiTE antibodies have been shown to induce an immunological ... tumor cells, which explains the activity of BiTE antibodies at very low concentrations and at very low ratios ...

Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma

... Lugano, 2008. About BiTE Antibodies BiTE(R) antibodies are designed to direct the body's cytotoxic, ... new therapeutic approach to cancer therapy. BiTE antibodies have been shown to induce an immunological ... tumor cells, which explains the activity of BiTE antibodies at very low concentrations and at very low ratios ...

Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives

... with Aegera Therapeutics. The HGS TRAIL receptor antibodies and small-molecule IAP inhibitors represent two ... cancers. HGS plans to develop its TRAIL receptor antibodies and IAP inhibitors in combination with ... HGS reacquired the rights to its TRAIL receptor antibodies from GSK in April 2008 in return for a reduction ...

Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas

... and CLL. About BiTE Antibodies BiTE(R) antibodies are designed to direct the body's cytotoxic, ... new therapeutic approach to cancer therapy. BiTE antibodies have been shown to induce an immunological ... tumor cells, which explains the activity of BiTE antibodies at very low concentrations and at very low ratios ...

CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date

... generates sustained high levels of neutralizing antibodies against the two most common cervical ... to date. Experts believe that neutralizing antibodies -- so-called because they have the ability to ... addition, the study found that the level of total antibodies induced by the candidate vaccine was sustained ...

Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors

... the treatment of haematological cancers. "BiTE antibodies enable the patients' own T cells to very ... to metastases." About BiTE Antibodies BiTE(R) antibodies are designed to direct the body's cytotoxic, ... new therapeutic approach to cancer therapy. BiTE antibodies have been shown to induce an immunological ...

Study Results of GAMMAGARD S/D and GAMMAGARD LIQUID in Patients with Mild-to-Moderate Alzheimer's Disease Announced

... Secondary endpoint results suggest that levels of antibodies against beta-amyloid were observed to have ... Relkin also reported observations that levels of antibodies against beta-amyloid increased in the ... IGIV products can contain blood group antibodies that may cause a positive direct antiglobulin ...

Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab

... on the surface of targeted cells, these anti-PS antibodies could create a unique tumor microenvironment, by ... and CEO of Peregrine. "We know that these antibodies can combat cancer by targeting the PS located on ... PS and its anti-inflammatory signals, our anti-PS antibodies unleash powerful pro-inflammatory effects ...

Preclinical Study Presented at AACR Annual Meeting Shows Peregrine's Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model

... Anti-PS Vascular Targeting antibodies - SAN DIEGO and TUSTIN, Calif., April 15 ... combining its anti-phosphatidylserine (anti-PS) antibodies and cytokines such as IL-2 to generate robust ... provides further evidence that our anti-PS antibodies have the potential to reverse the ...

Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study

... administered BiTE(R) antibodies(1). BiTE antibodies are designed to direct the body's cytotoxic, or ... routes of administration for MT110 and other BiTE antibodies to further enhance the quality of life of ... No. 2403. About BiTE Antibodies BiTE(R) antibodies are designed to direct the body's cytotoxic, ...

Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma

... ), a biopharmaceutical company developing novel antibodies for the treatment of cancer, inflammation and ... (AML) and melanoma (1). BiTE antibodies are designed to direct the body's cytotoxic, or ... Generation of human anti-CD33 and anti-MCSP BiTE antibodies used a novel human BiTE antibody platform that is ...

Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies

... CA, data showing that commercial anti-cancer antibodies trastuzumab (Herceptin(R); Genentech, ... successfully converted into a BiTE antibody. BiTE antibodies are designed to direct the body's cytotoxic, or ... of cancer and other diseases. All four BiTE antibodies were constructed using Micromet's ...

Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies

... have shown the potential efficacy of our anti-PS antibodies in combination with both existing and ... potential versatility of our anti-PS antibodies in combination cancer therapy. We look forward to ... clinical studies of bavituximab and other anti-PS antibodies in a broad range of anti-cancer regimens." Dr. ...
Other Contents
(Date:4/18/2014)... a twist to the story of how barnyard chickens came ... in the journal Proceedings of the National Academy of ... that lived 200-2300 years ago in Europe, researchers report that ... looked far different from the chickens we know today. , ... with modern domestic chickens -- such as their yellowish skin ...
(Date:4/17/2014)... the most densely forested and most densely populated quadrant ... human needs, values and practices. Disturbances associated with those ... and development, have set the stage for management issues ... reports. , The report Five anthropogenic factors that ... the Northern United States was published recently ...
(Date:4/17/2014)... New Rochelle, NY, April 17, 2014The development of stem ... on the ability to characterize stem cell populations based ... Cross have discovered a new marker that is highly ... human umbilical cord blood, which they describe in an ... journal from Mary Ann Liebert, Inc., publishers. The article ...
Breaking Biology News(10 mins):Ancient DNA offers clues to how barnyard chickens came to be 2Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3
(Date:4/17/2014)... presence of chronic inflammation in benign prostate tissue ... and this association was found even in those ... a study published in Cancer Epidemiology, Biomarkers ... Association for Cancer Research. , An analysis of ... the placebo arm of the Prostate Cancer Prevention ...
(Date:4/17/2014)... popular vaccine brands for children may not be the ... cost factors when choosing vaccines, driving the market toward ... a new study by University of Illinois researchers. , ... by numerous factors," says Sheldon H. Jacobson, a co-author ... and of mathematics at the U. of I. "In ...
(Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
(Date:4/17/2014)... Rochelle, NY, April 17, 2014U.S. military personnel who ... plus impact" concussive traumatic brain injury (TBI) were ... evacuated for other medical reasons. Differences in measures ... depression 6-12 months after injury are reported in ... a peer-reviewed journal from Mary Ann Liebert, Inc., ...
(Date:4/17/2014)... CHICAGO, IL, April 17, 2014-- Colic affects about one ... accounts for numerous pediatric visits during the first several ... of colic symptoms was showing promise; however, the April ... (BMJ2014;348:g2107; Sung, Valerie) reported on a study, "Probiotics ... probiotic L reuteri for infant colic ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
Other TagsOther Tags